GNH USA

Europe — EMA

Jivi (Damoctocog Alfa Pegol)

GNH USA supplies Jivi (Damoctocog Alfa Pegol), a recombinant factor VIII product for hemophilia A and perioperative management. Request a quote for supply.

Damoctocog Alfa Pegol

Request sourcing

1
Pack/s

What is Damoctocog Alfa Pegol?

Damoctocog alfa pegol, the active ingredient in Jivi, is a recombinant factor VIII product presented as a solution for injection for intravenous use. It replaces deficient factor VIII in patients with hemophilia A, helping to control and prevent bleeding episodes. The therapy is used for routine prophylaxis, on‑demand treatment of bleeding events, and peri‑operative management of individuals with congenital factor VIII deficiency.

GNH USA supplies Jivi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

What is Damoctocog Alfa Pegol used for?

Jivi, a recombinant factor VIII concentrate, acts on the intrinsic coagulation pathway to replace deficient factor VIII in hemophilia A. - Hemophilia A (congenital factor VIII deficiency): provides factor VIII replacement to prevent or control spontaneous and traumatic bleeding. - Perioperative management of hemophilia A: maintains adequate hemostasis during surgical procedures. - On‑demand treatment of bleeding episodes in hemophilia A: rapidly restores clotting ability to stop active bleeds.

What are the side effects of Damoctocog Alfa Pegol?

Jivi may be associated with a range of adverse reactions following intravenous administration.

Common Side Effects: - Injection site pain or erythema: mild discomfort at the infusion site - Headache: transient mild to moderate pain - Fever: low-grade temperature rise - Arthralgia: joint pain without swelling - Nausea: occasional upset stomach - Fatigue: general tiredness - Dizziness: brief light‑headed sensation - Mild rash: limited skin redness

Serious or Rare Side Effects: - Development of inhibitory antibodies: neutralizing factor VIII activity - Anaphylactic or severe allergic reactions: rapid onset breathing difficulty and hives - Thromboembolic events: clot formation in veins or arteries - Disseminated intravascular coagulation: widespread clotting and bleeding - Hemolysis: destruction of red blood cells - Severe hypotension: marked drop in blood pressure

What precautions apply to Damoctocog Alfa Pegol?

When using Jivi, several precautions should be observed to ensure safety and efficacy. - Monitor for inhibitor development: test for anti‑factor VIII antibodies regularly. - Assess for allergic reactions: watch for rash, itching, or respiratory symptoms during infusion. - Use with caution in patients with a history of thrombosis: evaluate clotting risk before administration. - Avoid in individuals with known hypersensitivity to any component of the product: confirm allergy history. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

What does Damoctocog Alfa Pegol interact with?

Jivi can interact with other medicines, influencing its effectiveness or safety.

Major Interactions (Avoid): - Concurrent use of other factor VIII concentrates: may increase risk of inhibitor formation. - Immunosuppressive agents that alter immune response: could affect antibody development.

Moderate Interactions (Monitor Closely): - Heparin or low‑molecular‑weight heparin: monitor coagulation parameters. - Antiplatelet drugs (e.g., aspirin, clopidogrel): increased bleeding risk. - Antifibrinolytics (e.g., tranexamic acid): may enhance clot stability, watch for thrombosis. - Live vaccines: potential altered immune response.

Frequently asked questions

What is Jivi used for?+
Jivi is a recombinant factor VIII concentrate indicated for the treatment and prevention of bleeding in patients with hemophilia A, including routine prophylaxis, on‑demand control of bleeding episodes, and peri‑operative management during surgery.
How does Damoctocog alfa pegol work?+
Damoctocog alfa pegol is a PEGylated recombinant factor VIII that restores functional factor VIII activity in the intrinsic coagulation pathway. By forming the tenase complex with factor IXa, it enables conversion of factor X to Xa, leading to thrombin generation and stable fibrin clot formation in individuals lacking endogenous factor VIII.
What is the usual dose of Jivi?+
The dosage of Jivi is individualized by the prescribing healthcare professional based on the patient’s weight, severity of factor VIII deficiency, type of bleed, and surgical requirements. Dosing regimens are calculated to achieve target factor VIII activity levels and are adjusted according to clinical response and laboratory monitoring.
Is Jivi safe during pregnancy or breastfeeding?+
Safety data for Jivi in pregnant or lactating women are limited, and the product is classified as pregnancy category unknown. Use during pregnancy or breastfeeding should only occur if the potential benefit justifies the potential risk, and decisions should be made by the treating physician in consultation with obstetric specialists.
How do I order Jivi from GNH USA?+
To place an order, submit an enquiry on the Jivi product page at gnh-usa.com, specifying the required quantity. GNH USA works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details, and the necessary import documentation.
How does Jivi compare with other factor VIII products?+
Jivi is a PEGylated recombinant factor VIII, offering an extended half‑life compared with standard non‑PEGylated factor VIII concentrates. This longer circulation time can reduce infusion frequency for prophylaxis, while maintaining comparable efficacy in controlling bleeding. Choice of product depends on individual patient needs, inhibitor status, and physician preference.
What are the storage and handling requirements for Jivi?+
Jivi must be stored at 2‑8 °C (refrigerated) in its original packaging, protected from light. Do not freeze or shake the vial. If temperature excursions occur, discard the product according to the manufacturer’s guidelines. Proper cold‑chain management is essential to maintain product stability.
How is Jivi administered?+
Jivi is supplied as a sterile solution for injection and is administered intravenously. The infusion is given through a peripheral or central venous line, typically over several minutes, depending on the prescribed dose and patient tolerance. Administration should be performed by qualified healthcare personnel following aseptic technique.
What are the most serious risks associated with Jivi?+
The most serious risks include the development of inhibitory antibodies that neutralize factor VIII activity, severe allergic or anaphylactic reactions, and rare thromboembolic events such as deep‑vein thrombosis or pulmonary embolism. Patients should be monitored closely for signs of these complications, and immediate medical attention is required if they occur.
Who should not use Jivi?+
Jivi is contraindicated in individuals with known hypersensitivity to Damoctocog alfa pegol or any of the excipients in the formulation. Patients with a history of severe allergic reactions to factor VIII products should avoid Jivi, and alternative therapies should be considered under medical supervision.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Damoctocog Alfa Pegol
Route
Intravenous Use
Manufacturer
Bayer Ag
Origin
EU

Related products

Jivi

Jivi

Damoctocog Alfa Pegol

Bayer Ag
EU
Jivi

Jivi

Damoctocog Alfa Pegol

Bayer Ag
EU
Jivi

Jivi

Damoctocog Alfa Pegol

Bayer Ag
EU